Description

Erdafitinib Tablets 4 mg

Erdafitinib Tablets 4 mg contain erdafitinib, a targeted prescription medicine used for certain types of advanced or metastatic urothelial cancer in eligible patients with specific genetic alterations. Erdafitinib belongs to a class of medicines known as FGFR inhibitors and works by blocking signals from abnormal fibroblast growth factor receptors (FGFRs) that can contribute to cancer cell growth.

Erdafitinib 4 mg tablets are intended for use under the supervision of a qualified healthcare professional. Treatment suitability may depend on the patient’s cancer type, FGFR alteration status, previous treatments, and overall health.

Key Features of Erdafitinib Tablets 4 mg

• Contains erdafitinib 4 mg
• Targeted therapy for eligible patients with specific FGFR alterations
• Used in the treatment of certain advanced or metastatic urothelial cancers
• Prescription medicine requiring medical supervision
• Available as an oral tablet

Frequently Asked Questions

1. What are Erdafitinib Tablets 4 mg used for?
Erdafitinib is used to treat certain patients with advanced or metastatic urothelial cancer whose tumors have specific susceptible FGFR genetic alterations, as determined by appropriate testing.

2. How does Erdafitinib 4 mg work?
Erdafitinib is an FGFR inhibitor. It blocks activity from certain FGFR proteins involved in cancer cell growth and survival, which may help slow the progression of cancer.

3. How should Erdafitinib Tablets 4 mg be taken?
Erdafitinib should be taken exactly as prescribed by your doctor. Do not change the dose, frequency, or duration of treatment without medical advice.

4. What are the possible side effects of Erdafitinib?
Possible side effects can include changes in phosphate levels, mouth sores, dry mouth, diarrhea, dry skin, nail changes, and eye-related problems. Your healthcare provider will monitor you for treatment-related effects.

5. Is Erdafitinib 4 mg suitable for everyone with bladder cancer?
No. Erdafitinib is not appropriate for every patient with bladder cancer or urothelial cancer. Treatment generally depends on factors such as the cancer’s FGFR alteration status and previous treatment history. A healthcare professional should determine whether it is appropriate.